메뉴 건너뛰기




Volumn 41, Issue 3, 2009, Pages 124-135

Novel drug delivery systems for retinal diseases: A review

Author keywords

Corticosteroids; Drug delivery, eye; Retina

Indexed keywords

BEVACIZUMAB; BUDESONIDE; CELECOXIB; CORTICOSTEROID; CYCLOSPORIN A; CYPHER; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; I VATION; MEDIDUR; MICROSPHERE; PEGAPTANIB; PREDNISOLONE; RANIBIZUMAB; RAPAMYCIN; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TRIESENCE; TRIVARIS; UNCLASSIFIED DRUG; DRUG;

EID: 62849109726     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209665     Document Type: Review
Times cited : (51)

References (112)
  • 1
    • 28244476435 scopus 로고    scopus 로고
    • Age-related eye diseases: An emerging challenge for public health professionals
    • Gohdes DM, Balamurugan A, Larsen BA, Maylahn C: Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 2005;2:A17.
    • (2005) Prev Chronic Dis , vol.2
    • Gohdes, D.M.1    Balamurugan, A.2    Larsen, B.A.3    Maylahn, C.4
  • 2
    • 34848907420 scopus 로고    scopus 로고
    • Overview of epidemiologic studies of diabetic retinopathy
    • Klein BE: Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007; 14:179-183.
    • (2007) Ophthalmic Epidemiol , vol.14 , pp. 179-183
    • Klein, B.E.1
  • 5
    • 34547869213 scopus 로고    scopus 로고
    • Pharmacothera-pies for diabetic retinopathy: Present and future
    • Schwartz SG, Flynn HW Jr: Pharmacothera-pies for diabetic retinopathy: present and future. Exp Diabetes Res 2007;2007:52487.
    • (2007) Exp Diabetes Res 2007 , pp. 52487
    • Schwartz, S.G.1    Flynn Jr, H.W.2
  • 6
    • 0032797880 scopus 로고    scopus 로고
    • Drusen in age-related macular degeneration: Pathogenesis, natural course, and laser pho-tocoagulation-induced regression
    • Abdelsalam A, Del Priore L, Zarbin MA: Drusen in age-related macular degeneration: pathogenesis, natural course, and laser pho-tocoagulation-induced regression. Surv Ophthalmol 1999;44:1-29.
    • (1999) Surv Ophthalmol , vol.44 , pp. 1-29
    • Abdelsalam, A.1    Del Priore, L.2    Zarbin, M.A.3
  • 7
    • 0032448463 scopus 로고    scopus 로고
    • Age-related macular degeneration: Review of pathogenesis
    • Zarbin MA: Age-related macular degeneration: review of pathogenesis. Eur J Ophthalmol 1998;8:199-206.
    • (1998) Eur J Ophthalmol , vol.8 , pp. 199-206
    • Zarbin, M.A.1
  • 8
    • 44349085868 scopus 로고    scopus 로고
    • Retinal precursors and the development of geographic atrophy in age-related macular degeneration
    • Klein ML, Ferris FL 3rd, Armstrong J, et al: Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 2008; 115: 1026-1031.
    • (2008) Ophthalmology , vol.115 , pp. 1026-1031
    • Klein, M.L.1    Ferris 3rd, F.L.2    Armstrong, J.3
  • 10
    • 0023224438 scopus 로고
    • Pathophysiology of age-related macular degeneration
    • Young RW: Pathophysiology of age-related macular degeneration. Surv Ophthalmol 1987;31:291-306.
    • (1987) Surv Ophthalmol , vol.31 , pp. 291-306
    • Young, R.W.1
  • 11
    • 33846475583 scopus 로고    scopus 로고
    • Thermal laser treatment in AMD: Therapeutic and prophylactic
    • Cukras C, Fine SL: Thermal laser treatment in AMD: therapeutic and prophylactic. Int Ophthalmol Clin 2007;47:75-93.
    • (2007) Int Ophthalmol Clin , vol.47 , pp. 75-93
    • Cukras, C.1    Fine, S.L.2
  • 13
    • 33749451356 scopus 로고    scopus 로고
    • Ra-nibizumab versus verteporfin for neovascular age-related macular degeneration
    • Brown DM, Kaiser PK, Michels M, et al: Ra-nibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
    • (2006) N Engl J Med , vol.355 , pp. 1432-1444
    • Brown, D.M.1    Kaiser, P.K.2    Michels, M.3
  • 14
    • 33749445317 scopus 로고    scopus 로고
    • Ra-nibizumab for neovascular age-related macular degeneration
    • Rosenfeld PJ, Brown DM, Heier JS, et al: Ra-nibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1419-1431.
    • (2006) N Engl J Med , vol.355 , pp. 1419-1431
    • Rosenfeld, P.J.1    Brown, D.M.2    Heier, J.S.3
  • 15
    • 34548721616 scopus 로고    scopus 로고
    • Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients
    • Brown DM, Regillo CD: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007; 144:627-637.
    • (2007) Am J Ophthalmol , vol.144 , pp. 627-637
    • Brown, D.M.1    Regillo, C.D.2
  • 18
    • 41149178633 scopus 로고    scopus 로고
    • Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascular-ization and retinal edema
    • Doukas J, Mahesh S, Umeda N, et al: Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascular-ization and retinal edema. J Cell Physiol 2008;216:29-37.
    • (2008) J Cell Physiol , vol.216 , pp. 29-37
    • Doukas, J.1    Mahesh, S.2    Umeda, N.3
  • 19
    • 45749143528 scopus 로고    scopus 로고
    • Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits
    • Scheppke L, Aguilar E, Gariano RF, et al: Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest 2008; 118:2337-2346.
    • (2008) J Clin Invest , vol.118 , pp. 2337-2346
    • Scheppke, L.1    Aguilar, E.2    Gariano, R.F.3
  • 20
    • 50449090755 scopus 로고    scopus 로고
    • Targeting intraocular neovascu-larization and edema - one drop at a time
    • Aiello LP: Targeting intraocular neovascu-larization and edema - one drop at a time. N Engl J Med 2008;359:967-969.
    • (2008) N Engl J Med , vol.359 , pp. 967-969
    • Aiello, L.P.1
  • 21
    • 28444440585 scopus 로고    scopus 로고
    • Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis
    • Myles ME, Neumann DM, Hill JM: Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005;57: 2063-2079.
    • (2005) Adv Drug Deliv Rev , vol.57 , pp. 2063-2079
    • Myles, M.E.1    Neumann, D.M.2    Hill, J.M.3
  • 22
    • 33751268869 scopus 로고    scopus 로고
    • Intraocular implants for extended drug delivery: Therapeutic applications
    • Bourges JL, Bloquel C, Thomas A, et al: Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006;58:1182-1202.
    • (2006) Adv Drug Deliv Rev , vol.58 , pp. 1182-1202
    • Bourges, J.L.1    Bloquel, C.2    Thomas, A.3
  • 23
    • 33751172532 scopus 로고    scopus 로고
    • Ocular delivery of nucleic acids: Antisense oligonucleotides, apta-mers and siRNA
    • Fattal E, Bochot A: Ocular delivery of nucleic acids: antisense oligonucleotides, apta-mers and siRNA. Adv Drug Deliv Rev 2006; 58:1203-1223.
    • (2006) Adv Drug Deliv Rev , vol.58 , pp. 1203-1223
    • Fattal, E.1    Bochot, A.2
  • 25
    • 34249787025 scopus 로고    scopus 로고
    • Ocular drugdelivery: Nanomedicine applications
    • Vandervoort J, Ludwig A: Ocular drugdelivery: nanomedicine applications. Nanomed 2007;2:11-21.
    • (2007) Nanomed , vol.2 , pp. 11-21
    • Vandervoort, J.1    Ludwig, A.2
  • 27
    • 35048821557 scopus 로고    scopus 로고
    • Transport barriers in transscleral drug delivery for retinal diseases
    • Kim SH, Lutz RJ, Wang NS, Robinson MR: Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 2007;39:244-254.
    • (2007) Ophthalmic Res , vol.39 , pp. 244-254
    • Kim, S.H.1    Lutz, R.J.2    Wang, N.S.3    Robinson, M.R.4
  • 28
    • 31344468895 scopus 로고    scopus 로고
    • A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone ace-tonide
    • Robinson MR, Lee SS, Kim H, et al: A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone ace-tonide. Exp Eye Res 2006;82:479-487.
    • (2006) Exp Eye Res , vol.82 , pp. 479-487
    • Robinson, M.R.1    Lee, S.S.2    Kim, H.3
  • 30
    • 0020660753 scopus 로고
    • Physiology of the choroidal vascular bed
    • Bill A, Sperber G, Ujiie K: Physiology of the choroidal vascular bed. Int Ophthalmol 1983;6:101-107.
    • (1983) Int Ophthalmol , vol.6 , pp. 101-107
    • Bill, A.1    Sperber, G.2    Ujiie, K.3
  • 31
    • 0016907184 scopus 로고
    • Observations on the corrosion costs of the choriocapillaries (author's transl)
    • Araki M: Observations on the corrosion costs of the choriocapillaries (author's transl). Nippon Ganka Gakkai Zasshi 1976; 80:315-326.
    • (1976) Nippon Ganka Gakkai Zasshi , vol.80 , pp. 315-326
    • Araki, M.1
  • 32
    • 0000510983 scopus 로고
    • The drainage of albumin from the uvea
    • Bill A: The drainage of albumin from the uvea. Exp Eye Res 1964; 75:179-187.
    • (1964) Exp Eye Res , vol.75 , pp. 179-187
    • Bill, A.1
  • 33
    • 3242885512 scopus 로고    scopus 로고
    • Controlled drug release from an ocular implant: An evaluation using dynamic three-dimensional magnetic resonance imaging
    • Kim H, Robinson MR, Lizak MJ, et al: Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci 2004;45:2722-2731.
    • (2004) Invest Ophthalmol Vis Sci , vol.45 , pp. 2722-2731
    • Kim, H.1    Robinson, M.R.2    Lizak, M.J.3
  • 34
    • 10644248274 scopus 로고    scopus 로고
    • Trans-Tenon retrobulbar triamcinolone infusion for chronic macular edema in central and branch retinal vein occlusion
    • Wakabayashi T, Okada AA, Morimura Y, et al: Trans-Tenon retrobulbar triamcinolone infusion for chronic macular edema in central and branch retinal vein occlusion. Retina 2004;24:964-967.
    • (2004) Retina , vol.24 , pp. 964-967
    • Wakabayashi, T.1    Okada, A.A.2    Morimura, Y.3
  • 35
    • 3042666103 scopus 로고    scopus 로고
    • Trans-Tenon's retrobulbar triamcinolone infusion for diffuse diabetic macular edema
    • Ohguro N, Okada AA, Tano Y: Trans-Tenon's retrobulbar triamcinolone infusion for diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2004;242:444-445.
    • (2004) Graefes Arch Clin Exp Ophthalmol , vol.242 , pp. 444-445
    • Ohguro, N.1    Okada, A.A.2    Tano, Y.3
  • 36
    • 32944465175 scopus 로고    scopus 로고
    • Intravit-real injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial
    • Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA: Intravit-real injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46: 3845-3849.
    • (2005) Invest Ophthalmol Vis Sci , vol.46 , pp. 3845-3849
    • Bonini-Filho, M.A.1    Jorge, R.2    Barbosa, J.C.3    Calucci, D.4    Cardillo, J.A.5    Costa, R.A.6
  • 37
    • 0037336290 scopus 로고    scopus 로고
    • Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a cor-ticosteroid capable of inhibiting VEGF expression
    • Kompella UB, Bandi N, Ayalasomayajula SP: Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a cor-ticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 2003;44: 1192-1201.
    • (2003) Invest Ophthalmol Vis Sci , vol.44 , pp. 1192-1201
    • Kompella, U.B.1    Bandi, N.2    Ayalasomayajula, S.P.3
  • 38
    • 6344284095 scopus 로고    scopus 로고
    • Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration
    • Ayalasomayajula SP, Kompella UB: Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res 2004;21:1797-1804.
    • (2004) Pharm Res , vol.21 , pp. 1797-1804
    • Ayalasomayajula, S.P.1    Kompella, U.B.2
  • 39
    • 15744404419 scopus 로고    scopus 로고
    • Subcon-junctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model
    • Ayalasomayajula SP, Kompella UB: Subcon-junctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol 2005; 511:191-198.
    • (2005) Eur J Pharmacol , vol.511 , pp. 191-198
    • Ayalasomayajula, S.P.1    Kompella, U.B.2
  • 40
    • 0033843428 scopus 로고    scopus 로고
    • A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: Subconjunctival tolerance and in vitro release
    • Zignani M, Einmahl S, Baeyens V, et al: A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: subconjunctival tolerance and in vitro release. Eur J Pharm Biopharm 2000;50:251-255.
    • (2000) Eur J Pharm Biopharm , vol.50 , pp. 251-255
    • Zignani, M.1    Einmahl, S.2    Baeyens, V.3
  • 41
    • 0037726627 scopus 로고    scopus 로고
    • Gilbert JA, Simpson AE, Rudnick DE, Geroski DH, Aaberg TM Jr, Edelhauser HF: Trans-scleral permeability and intraocular concentrations of cisplatin from a collagen matrix. J Control Release 2003;89:409-417
    • Gilbert JA, Simpson AE, Rudnick DE, Geroski DH, Aaberg TM Jr, Edelhauser HF: Trans-scleral permeability and intraocular concentrations of cisplatin from a collagen matrix. J Control Release 2003;89:409-417.
  • 42
    • 0029769636 scopus 로고    scopus 로고
    • In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(D,L-lactide-co-glycolide)
    • Wang G, Tucker IG, Roberts MS, Hirst LW: In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(D,L-lactide-co-glycolide). Pharm Res 1996; 13:1059-1064.
    • (1996) Pharm Res , vol.13 , pp. 1059-1064
    • Wang, G.1    Tucker, I.G.2    Roberts, M.S.3    Hirst, L.W.4
  • 43
    • 0037809363 scopus 로고    scopus 로고
    • Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device
    • Okabe K, Kimura H, Okabe J, Kato A, Kunou N, Ogura Y: Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest Ophthalmol Vis Sci 2003;44:2702-2707.
    • (2003) Invest Ophthalmol Vis Sci , vol.44 , pp. 2702-2707
    • Okabe, K.1    Kimura, H.2    Okabe, J.3    Kato, A.4    Kunou, N.5    Ogura, Y.6
  • 44
    • 0037308517 scopus 로고    scopus 로고
    • Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate
    • Okabe J, Kimura H, Kunou N, Okabe K, Kato A, Ogura Y: Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis Sci 2003;44:740-744.
    • (2003) Invest Ophthalmol Vis Sci , vol.44 , pp. 740-744
    • Okabe, J.1    Kimura, H.2    Kunou, N.3    Okabe, K.4    Kato, A.5    Ogura, Y.6
  • 45
    • 0347358065 scopus 로고    scopus 로고
    • Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant
    • Kato A, Kimura H, Okabe K, Okabe J, Kunou N, Ogura Y: Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest Ophthalmol Vis Sci 2004;45:238-244.
    • (2004) Invest Ophthalmol Vis Sci , vol.45 , pp. 238-244
    • Kato, A.1    Kimura, H.2    Okabe, K.3    Okabe, J.4    Kunou, N.5    Ogura, Y.6
  • 46
    • 0034114629 scopus 로고    scopus 로고
    • Transscleral delivery of bioactive protein to the choroid and retina
    • Ambati J, Gragoudas ES, Miller JW, et al: Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000;41:1186-1191.
    • (2000) Invest Ophthalmol Vis Sci , vol.41 , pp. 1186-1191
    • Ambati, J.1    Gragoudas, E.S.2    Miller, J.W.3
  • 47
    • 13944251659 scopus 로고    scopus 로고
    • Effect of benzalkonium chloride on transscleral drug delivery
    • Okabe K, Kimura H, Okabe J, et al: Effect of benzalkonium chloride on transscleral drug delivery. Invest Ophthalmol Vis Sci 2005;46: 703-708.
    • (2005) Invest Ophthalmol Vis Sci , vol.46 , pp. 703-708
    • Okabe, K.1    Kimura, H.2    Okabe, J.3
  • 48
    • 0037299842 scopus 로고    scopus 로고
    • Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): Interim (month 6) analysis of clinical safety and efficacy
    • D'Amico DJ, Goldberg MF, Hudson H, et al: Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003; 23:14-23.
    • (2003) Retina , vol.23 , pp. 14-23
    • D'Amico, D.J.1    Goldberg, M.F.2    Hudson, H.3
  • 49
    • 0344442766 scopus 로고    scopus 로고
    • Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: Twelvemonth clinical outcomes
    • discussion 2384-2385
    • D'Amico DJ, Goldberg MF, Hudson H, et al: Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelvemonth clinical outcomes. Ophthalmology 2003;110:2372-2383; discussion 2384-2385.
    • (2003) Ophthalmology , vol.110 , pp. 2372-2383
    • D'Amico, D.J.1    Goldberg, M.F.2    Hudson, H.3
  • 50
    • 24944566042 scopus 로고    scopus 로고
    • Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema
    • Cardillo JA, Melo LA Jr, Costa RA, et al: Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-1563.
    • (2005) Ophthalmology , vol.112 , pp. 1557-1563
    • Cardillo, J.A.1    Melo Jr, L.A.2    Costa, R.A.3
  • 51
    • 1042301272 scopus 로고    scopus 로고
    • Drug delivery to the posterior segment of the eye. III: The effect of parallel elimination pathway on the vitreous drug level after subconjunctival injection
    • Lee TW, Robinson JR: Drug delivery to the posterior segment of the eye. III: the effect of parallel elimination pathway on the vitreous drug level after subconjunctival injection. J Ocul Pharmacol Ther 2004;20:55-64.
    • (2004) J Ocul Pharmacol Ther , vol.20 , pp. 55-64
    • Lee, T.W.1    Robinson, J.R.2
  • 52
    • 33745655043 scopus 로고    scopus 로고
    • A novel bioerodible deep scleral lamellar cy-closporine implant for uveitis
    • Gilger BC, Salmon JH, Wilkie DA, et al: A novel bioerodible deep scleral lamellar cy-closporine implant for uveitis. Invest Ophthalmol Vis Sci 2006;47:2596-2605.
    • (2006) Invest Ophthalmol Vis Sci , vol.47 , pp. 2596-2605
    • Gilger, B.C.1    Salmon, J.H.2    Wilkie, D.A.3
  • 53
    • 33750086968 scopus 로고    scopus 로고
    • Cannula-tion of the suprachoroidal space: A novel drug delivery methodology to the posterior segment
    • Olsen TW, Feng X, Wabner K, et al: Cannula-tion of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol 2006; 142:777-787.
    • (2006) Am J Ophthalmol , vol.142 , pp. 777-787
    • Olsen, T.W.1    Feng, X.2    Wabner, K.3
  • 54
    • 67349252651 scopus 로고    scopus 로고
    • Drug delivery to the suprachoroidal space shows promise
    • March/April
    • Olsen TW: Drug delivery to the suprachoroidal space shows promise. Retina Today 2007; March/April:36-39.
    • (2007) Retina Today , pp. 36-39
    • Olsen, T.W.1
  • 55
    • 3042763334 scopus 로고    scopus 로고
    • Ocular pharmacoki-netics of fluocinolone acetonide after Re-tisert intravitreal implantation in rabbits over a 1-year period
    • Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA: Ocular pharmacoki-netics of fluocinolone acetonide after Re-tisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269-275.
    • (2004) J Ocul Pharmacol Ther , vol.20 , pp. 269-275
    • Driot, J.Y.1    Novack, G.D.2    Rittenhouse, K.D.3    Milazzo, C.4    Pearson, P.A.5
  • 56
    • 67349277307 scopus 로고    scopus 로고
    • Dexamethasone posterior segment drug delivery system: Pharmacokinetics in vitrec-tomized and non-vitrectomized eyes
    • Indian Wells
    • Welty D, Kuppermann BD, Chang-Lin JE, et al: Dexamethasone posterior segment drug delivery system: pharmacokinetics in vitrec-tomized and non-vitrectomized eyes. 25th Annual Meet Am Soc Retina Specialists, Indian Wells, 2007.
    • (2007) 25th Annual Meet Am Soc Retina Specialists
    • Welty, D.1    Kuppermann, B.D.2    Chang-Lin, J.E.3
  • 58
    • 16344389598 scopus 로고    scopus 로고
    • Complications of intravitreal injection of triamcinolone acetonide
    • Ozkiris A, Erkilic K: Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005;40:63-68.
    • (2005) Can J Ophthalmol , vol.40 , pp. 63-68
    • Ozkiris, A.1    Erkilic, K.2
  • 59
    • 33947529092 scopus 로고    scopus 로고
    • Intravitreal triamcinolone acetonide for diabetic retinopathy
    • Jonas JB: Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol 2007;39:96-110.
    • (2007) Dev Ophthalmol , vol.39 , pp. 96-110
    • Jonas, J.B.1
  • 60
    • 34548355065 scopus 로고    scopus 로고
    • The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials
    • Bhavsar AR, Ip MS, Glassman AR: The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007; 144:454-456.
    • (2007) Am J Ophthalmol , vol.144 , pp. 454-456
    • Bhavsar, A.R.1    Ip, M.S.2    Glassman, A.R.3
  • 62
    • 0022347471 scopus 로고
    • Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study
    • Early Treatment Diabetic Retinopathy Study research group
    • Early Treatment Diabetic Retinopathy Study research group: Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103:1796-1806.
    • (1985) Arch Ophthalmol , vol.103 , pp. 1796-1806
  • 63
    • 0021874413 scopus 로고
    • Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate
    • Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985; 103:708-711.
    • (1985) Arch Ophthalmol , vol.103 , pp. 708-711
    • Ishibashi, T.1    Miki, K.2    Sorgente, N.3    Patterson, R.4    Ryan, S.J.5
  • 65
    • 0029620301 scopus 로고
    • Exudative macular degeneration and intravitreal triamcinolone: A pilot study
    • Penfold PL, Gyory JF, Hunyor AB, Billson FA: Exudative macular degeneration and intravitreal triamcinolone: a pilot study. Aust NZ J Ophthalmol 1995;23:293-298.
    • (1995) Aust NZ J Ophthalmol , vol.23 , pp. 293-298
    • Penfold, P.L.1    Gyory, J.F.2    Hunyor, A.B.3    Billson, F.A.4
  • 66
    • 0034886327 scopus 로고    scopus 로고
    • Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema
    • Jonas JB, Sofker A: Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132:425-427.
    • (2001) Am J Ophthalmol , vol.132 , pp. 425-427
    • Jonas, J.B.1    Sofker, A.2
  • 67
    • 0033400347 scopus 로고    scopus 로고
    • The pathogenesis of edema in diabetic maculopathy
    • Antcliff RJ, Marshall J: The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999; 14:223-232.
    • (1999) Semin Ophthalmol , vol.14 , pp. 223-232
    • Antcliff, R.J.1    Marshall, J.2
  • 68
    • 33750597534 scopus 로고    scopus 로고
    • Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease
    • Antonetti DA, Barber AJ, Bronson SK, et al: Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006;55:2401-2411.
    • (2006) Diabetes , vol.55 , pp. 2401-2411
    • Antonetti, D.A.1    Barber, A.J.2    Bronson, S.K.3
  • 69
    • 0036240895 scopus 로고    scopus 로고
    • Intravitreal triamcinolone for refractory diabetic macular edema
    • Martidis A, Duker JS, Greenberg PB, et al: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109:920-927.
    • (2002) Ophthalmology , vol.109 , pp. 920-927
    • Martidis, A.1    Duker, J.S.2    Greenberg, P.B.3
  • 70
    • 0842267262 scopus 로고    scopus 로고
    • Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial
    • discussion 224-225
    • Massin P, Audren F, Haouchine B, et al: Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111:218-224; discussion 224-225.
    • (2004) Ophthalmology , vol.111 , pp. 218-224
    • Massin, P.1    Audren, F.2    Haouchine, B.3
  • 72
    • 21244445737 scopus 로고    scopus 로고
    • Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema
    • Bakri SJ, Shah A, Falk NS, Beer PM: Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema. Eye 2005;19:686-688.
    • (2005) Eye , vol.19 , pp. 686-688
    • Bakri, S.J.1    Shah, A.2    Falk, N.S.3    Beer, P.M.4
  • 73
    • 7444245438 scopus 로고    scopus 로고
    • Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial
    • Sutter FK, Simpson JM, Gillies MC: Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004; 111:2044-2049.
    • (2004) Ophthalmology , vol.111 , pp. 2044-2049
    • Sutter, F.K.1    Simpson, J.M.2    Gillies, M.C.3
  • 74
    • 33747623255 scopus 로고    scopus 로고
    • Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial
    • Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
    • (2006) Ophthalmology , vol.113 , pp. 1533-1538
    • Gillies, M.C.1    Sutter, F.K.2    Simpson, J.M.3    Larsson, J.4    Ali, H.5    Zhu, M.6
  • 75
    • 33749602030 scopus 로고    scopus 로고
    • One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion
    • Gregori NZ, Rosenfeld PJ, Puliafito CA, et al: One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006;26:889-895.
    • (2006) Retina , vol.26 , pp. 889-895
    • Gregori, N.Z.1    Rosenfeld, P.J.2    Puliafito, C.A.3
  • 76
    • 34347223601 scopus 로고    scopus 로고
    • The effect of intravitreal triamcinolone on intraocular pressure
    • Kramar M, Vu L, Whitson JT, He YG: The effect of intravitreal triamcinolone on intraocular pressure. Curr Med Res Opin 2007; 23:1253-1258.
    • (2007) Curr Med Res Opin , vol.23 , pp. 1253-1258
    • Kramar, M.1    Vu, L.2    Whitson, J.T.3    He, Y.G.4
  • 77
    • 34548509483 scopus 로고    scopus 로고
    • Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema
    • Batioglu F, Ozmert E, Parmak N, Celik S: Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. Int Ophthalmol 2007;27:299-306.
    • (2007) Int Ophthalmol , vol.27 , pp. 299-306
    • Batioglu, F.1    Ozmert, E.2    Parmak, N.3    Celik, S.4
  • 78
    • 38049141027 scopus 로고    scopus 로고
    • Short-term complications of intravitreal injection of triamcinolone acetonide
    • Roth DB, Realini T, Feuer WJ, et al: Short-term complications of intravitreal injection of triamcinolone acetonide. Retina 2008;28: 66-70.
    • (2008) Retina , vol.28 , pp. 66-70
    • Roth, D.B.1    Realini, T.2    Feuer, W.J.3
  • 79
    • 26944488400 scopus 로고    scopus 로고
    • Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide
    • Wang LC, Yang CM: Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul Immunol Inflamm 2005;13:295-300.
    • (2005) Ocul Immunol Inflamm , vol.13 , pp. 295-300
    • Wang, L.C.1    Yang, C.M.2
  • 80
    • 19944432858 scopus 로고    scopus 로고
    • Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection
    • Moshfeghi DM, Kaiser PK, Bakri SJ, et al: Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2005; 36:24-29.
    • (2005) Ophthalmic Surg Lasers Imaging , vol.36 , pp. 24-29
    • Moshfeghi, D.M.1    Kaiser, P.K.2    Bakri, S.J.3
  • 81
    • 34548336565 scopus 로고    scopus 로고
    • Effects of intravitreal triamcinolone acetonide injection with and without preservative
    • Maia M, Farah ME, Belfort RN, et al: Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 2007;91:1122-1124.
    • (2007) Br J Ophthalmol , vol.91 , pp. 1122-1124
    • Maia, M.1    Farah, M.E.2    Belfort, R.N.3
  • 82
    • 0019192332 scopus 로고
    • The efficacy of intraarticular steroids in osteoarthritis: A double-blind study
    • Friedman DM, Moore ME: The efficacy of intraarticular steroids in osteoarthritis: a double-blind study. J Rheumatol 1980; 7: 850-856.
    • (1980) J Rheumatol , vol.7 , pp. 850-856
    • Friedman, D.M.1    Moore, M.E.2
  • 83
    • 0000545881 scopus 로고
    • Inflammatory reaction after intrasynovial injection of micro-crystalline adrenocorticosteroid esters
    • McCarty DJ Jr, Hogan JM: Inflammatory reaction after intrasynovial injection of micro-crystalline adrenocorticosteroid esters. Arthritis Rheum 1964;7:359-367.
    • (1964) Arthritis Rheum , vol.7 , pp. 359-367
    • McCarty Jr, D.J.1    Hogan, J.M.2
  • 84
    • 50249149459 scopus 로고    scopus 로고
    • A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema
    • Diabetic Retinopathy Clinical Research Network
    • Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115:1445-1446.
    • (2008) Ophthalmology , vol.115 , pp. 1445-1446
  • 87
    • 67349100827 scopus 로고    scopus 로고
    • Kuppermann BD, Williams GA, Blumenkranz MS, et al: Efficacy and safety of a novel intravitreous dexamethasone drug delivery system after applicator or incisional placement in patients with macular edema. Invest Ophthalmol Vis Sci 2006;47:E-ab-stract 5908.
    • Kuppermann BD, Williams GA, Blumenkranz MS, et al: Efficacy and safety of a novel intravitreous dexamethasone drug delivery system after applicator or incisional placement in patients with macular edema. Invest Ophthalmol Vis Sci 2006;47:E-ab-stract 5908.
  • 88
    • 33646925637 scopus 로고    scopus 로고
    • Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: Thirty-four-week results of a multicenter randomized clinical study
    • Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T: Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027.
    • (2006) Ophthalmology , vol.113 , pp. 1020-1027
    • Jaffe, G.J.1    Martin, D.2    Callanan, D.3    Pearson, P.A.4    Levy, B.5    Comstock, T.6
  • 89
    • 0033761752 scopus 로고    scopus 로고
    • Fluocinolone acetonide sustained drug delivery device to treat severe uveitis
    • Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P: Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 107:2024-2033.
    • (2000) Ophthalmology , vol.107 , pp. 2024-2033
    • Jaffe, G.J.1    Ben-Nun, J.2    Guo, H.3    Dunn, J.P.4    Ashton, P.5
  • 90
    • 67349168324 scopus 로고    scopus 로고
    • Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Implant Study Group: Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multicenter clinical trial (abstract). Invest Ophthalmol Vis Sci 2006;47:E-abstract 5442.
    • Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Implant Study Group: Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multicenter clinical trial (abstract). Invest Ophthalmol Vis Sci 2006;47:E-abstract 5442.
  • 91
    • 34047216320 scopus 로고    scopus 로고
    • Retisert: Is the new advance in treatment of uveitis a good one?
    • Mohammad DA, Sweet BV, Elner SG: Retisert: is the new advance in treatment of uveitis a good one? Ann Pharmacother 2007; 41:449-454.
    • (2007) Ann Pharmacother , vol.41 , pp. 449-454
    • Mohammad, D.A.1    Sweet, B.V.2    Elner, S.G.3
  • 92
    • 54249140002 scopus 로고    scopus 로고
    • Medidur Insert Technology
    • Mruthyunjaya P, Jaffe GJ: Medidur Insert Technology. Retinal Physician 2007 http://www.retinalphysician.com/article.aspx? article=100862.
    • (2007) Retinal Physician
    • Mruthyunjaya, P.1    Jaffe, G.J.2
  • 93
    • 67349094185 scopus 로고    scopus 로고
    • www.surmodics.com.
  • 94
    • 67349095204 scopus 로고    scopus 로고
    • Dugel PU, Cantrill HL, Eliott D, Mahmoud T, Avery R, Varner SE: Clinical safety and preliminary efficacy of an intravitreal triamcinolone implant (I-vation™ TA) in DME. Invest Ophthalmol Vis Sci 2007;48:E-ab-stract 1413.
    • Dugel PU, Cantrill HL, Eliott D, Mahmoud T, Avery R, Varner SE: Clinical safety and preliminary efficacy of an intravitreal triamcinolone implant (I-vation™ TA) in DME. Invest Ophthalmol Vis Sci 2007;48:E-ab-stract 1413.
  • 95
    • 67349193904 scopus 로고    scopus 로고
    • http://phx.corporateir.net/phoenix.zhtml?c=80353&p= irol-newsArticle&ID=1185643&highlight=.
    • http://phx.corporateir.net/phoenix.zhtml?c=80353&p= irol-newsArticle&ID=1185643&highlight=.
  • 97
    • 25844513658 scopus 로고    scopus 로고
    • A phase II randomized double-masked trial of pegaptanib, an anti-vascular endo-thelial growth factor aptamer, for diabetic macular edema
    • Cunningham ET Jr, Adamis AP, Altaweel M, et al: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endo-thelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112: 1747-1757.
    • (2005) Ophthalmology , vol.112 , pp. 1747-1757
    • Cunningham Jr, E.T.1    Adamis, A.P.2    Altaweel, M.3
  • 98
    • 33845191304 scopus 로고    scopus 로고
    • Vascular endothelial growth factor is a critical stimulus for diabetic macular edema
    • Nguyen QD, Tatlipinar S, Shah SM, et al: Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142:961-969.
    • (2006) Am J Ophthalmol , vol.142 , pp. 961-969
    • Nguyen, Q.D.1    Tatlipinar, S.2    Shah, S.M.3
  • 99
    • 34748876124 scopus 로고    scopus 로고
    • A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema
    • Scott IU, Edwards AR, Beck RW, et al: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114:1860-1867.
    • (2007) Ophthalmology , vol.114 , pp. 1860-1867
    • Scott, I.U.1    Edwards, A.R.2    Beck, R.W.3
  • 100
    • 28444434771 scopus 로고    scopus 로고
    • Regulatory aspects of drug approval for macular degeneration
    • Gryziewicz L: Regulatory aspects of drug approval for macular degeneration. Adv Drug Deliv Rev 2005;57:2092-2098.
    • (2005) Adv Drug Deliv Rev , vol.57 , pp. 2092-2098
    • Gryziewicz, L.1
  • 101
    • 38449100932 scopus 로고    scopus 로고
    • Anti-vascular endothelial growth factor therapy for ocular neovascular disease
    • Andreoli CM, Miller JW: Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-508.
    • (2007) Curr Opin Ophthalmol , vol.18 , pp. 502-508
    • Andreoli, C.M.1    Miller, J.W.2
  • 102
    • 34247562266 scopus 로고    scopus 로고
    • Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration
    • Chakravarthy U, Adamis AP, Cunningham ET Jr, et al: Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508-1525.
    • (2006) Ophthalmology , vol.113 , pp. 1508-1525
    • Chakravarthy, U.1    Adamis, A.P.2    Cunningham Jr, E.T.3
  • 103
    • 33745782355 scopus 로고    scopus 로고
    • Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
    • Rich RM, Rosenfeld PJ, Puliafito CA, et al: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
    • (2006) Retina , vol.26 , pp. 495-511
    • Rich, R.M.1    Rosenfeld, P.J.2    Puliafito, C.A.3
  • 104
    • 33845750072 scopus 로고    scopus 로고
    • Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration
    • Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM: Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-998.
    • (2006) Retina , vol.26 , pp. 994-998
    • Yoganathan, P.1    Deramo, V.A.2    Lai, J.C.3    Tibrewala, R.K.4    Fastenberg, D.M.5
  • 105
    • 0032864292 scopus 로고    scopus 로고
    • Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration
    • Mordenti J, Cuthbertson RA, Ferrara N, et al: Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27:536-544.
    • (1999) Toxicol Pathol , vol.27 , pp. 536-544
    • Mordenti, J.1    Cuthbertson, R.A.2    Ferrara, N.3
  • 106
    • 34047175559 scopus 로고    scopus 로고
    • Targeting VEGF-A to treat cancer and age-related macular degeneration
    • Ferrara N, Mass RD, Campa C, Kim R: Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007;58:491-504.
    • (2007) Annu Rev Med , vol.58 , pp. 491-504
    • Ferrara, N.1    Mass, R.D.2    Campa, C.3    Kim, R.4
  • 109
    • 34447634120 scopus 로고    scopus 로고
    • Treatment of exudative age-related macular degeneration: Many factors to consider
    • Olsen TW: Treatment of exudative age-related macular degeneration: many factors to consider. Am J Ophthalmol 2007; 144: 281-283.
    • (2007) Am J Ophthalmol , vol.144 , pp. 281-283
    • Olsen, T.W.1
  • 112
    • 67349256009 scopus 로고    scopus 로고
    • Bethke W: Present and future retinal implants. Rev Ophthalmol 2006; 13.http://www.revophth.com/index.asp?page=1-990.htm.
    • Bethke W: Present and future retinal implants. Rev Ophthalmol 2006; 13.http://www.revophth.com/index.asp?page=1-990.htm.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.